Get the Stockscreener App
22.04
2.56%
0.56
Kiniksa Pharmaceuticals International Plc stock is traded at $22.04, with a volume of 194.34K.
It is up +2.56% in the last 24 hours and down -10.01% over the past month.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
See More
Previous Close:
$21.48
Open:
$20.66
24h Volume:
194.34K
Relative Volume:
0.57
Market Cap:
$1.59B
Revenue:
$338.93M
Net Income/Loss:
$-10.23M
P/E Ratio:
-200.36
EPS:
-0.11
Net Cash Flow:
$30.31M
1W Performance:
-5.31%
1M Performance:
-10.01%
6M Performance:
+9.71%
1Y Performance:
+35.99%
1-Day Range:
$20.66
$22.11
1-Week Range:
$20.66
$23.86
52-Week Range:
$14.12
$28.15
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals International Plc
Sector
Phone
(781) 431-9100
Address
23 OLD BOND STREET, FLOOR 3, LONDON
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-20 | Reiterated | BofA Securities | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Dec-12-18 | Reiterated | Wedbush | Outperform |
| Jun-19-18 | Initiated | JMP Securities | Mkt Outperform |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Kiniksa Pharmaceuticals International PLC (KNSA) Trading Down 3. - GuruFocus.com
Kiniksa Pharmaceuticals International, plc Just Missed Earnings With A Surprise LossHere Are Analysts Latest Forecasts - Yahoo Finance
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2024 Earnings Call Transcript - Insider Monkey
Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earning - GuruFocus.com
Kiniksa Pharmaceuticals International Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Kiniksa Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks
Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings Call Highlights: Impressive ... - Yahoo Finance
Kiniksa Pharm's Revenue Surges 67% in Q3 - The Motley Fool
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Gap Down to $24.04 on Oct 29 - GuruFocus.com
Kiniksa Pharmaceuticals Q3 2024 Earnings: EPS Miss, Revenue Beats Estimates with $112.2 Million - GuruFocus.com
Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution - GlobeNewswire
Kiniksa Pharmaceuticals International, plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Exploring Kiniksa Pharmaceuticals's Earnings Expectations - Benzinga
What To Expect From Kiniksa Pharmaceuticals International PLC (K - GuruFocus.com
What To Expect From Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings - Yahoo Finance
Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning - GlobeNewswire
Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis - StockTitan
Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024 - GlobeNewswire
Kiniksa Pharmaceuticals COO Eben sells shares worth $456,790 - Investing.com India
Kiniksa Pharmaceuticals COO Eben sells shares worth $456,790 By Investing.com - Investing.com UK
High Growth Tech Stocks To Watch In October 2024 - Simply Wall St
What Makes Kiniksa Pharmaceuticals (KNSA) a Good Fit for 'Trend Investing' - Yahoo Finance
Baker Bros. Advisors LP Increases Stake in Kiniksa Pharmaceuticals - Yahoo Finance
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Average Rating of “Buy” from Analysts - Defense World
Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story (NASDAQ:KNSA) - Seeking Alpha
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis - The Manila Times
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa - GlobeNewswire
Kiniksa Pharmaceuticals COO sells shares worth over $437,000 By Investing.com - Investing.com Australia
Kiniksa Pharmaceuticals COO sells shares worth over $437,000 - Investing.com
Kiniksa Pharmaceuticals International Plc. (KNSA) looking to reclaim success with recent performance - SETE News
Rubric Capital Management LP Acquires 223,094 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Acadian Asset Management LLC - Defense World
Kiniksa stock draws buy at Jefferies (NASDAQ:KNSA) - Seeking Alpha
Insider Sale Alert: Kiniksa Pharmaceuticals International Plc. [KNSA] – Is it Time to sell? - Knox Daily
Kiniksa Pharmaceuticals exec sells over $1.7m in shares By Investing.com - Investing.com Australia
Kiniksa Pharmaceuticals exec sells over $1.7m in shares - Investing.com India
The Psychology of Kiniksa Pharmaceuticals International Plc. Inc. (KNSA) Price Performance: Understanding Market Sentiment - The InvestChronicle
Eben Tessari Sells 17,500 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock - Defense World
Kiniksa Pharmaceuticals COO sells shares worth over $470k - Investing.com
Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference - GlobeNewswire
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Reaches New 52-Week High at $27.96 - Defense World
KNSA (Kiniksa Pharmaceuticals International) Property, Plan - GuruFocus.com
Wells Fargo analysts initates an Overweight rating for Kiniksa Pharmaceuticals International Plc. (KNSA) - Knox Daily
Stocks of Kiniksa Pharmaceuticals International Plc. (KNSA) are poised to climb above their peers - SETE News
3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft Landing - Inkl
KNSA (Kiniksa Pharmaceuticals International) Profitability Rank : 2 (As of Jun. 2024) - GuruFocus.com
KNSA (Kiniksa Pharmaceuticals International) Treasury Stock : $0.0 Mil (As of Jun. 2024) - GuruFocus.com
KNSA (Kiniksa Pharmaceuticals International) Revenue : $338.9 Mil (TTM As of Jun. 2024) - GuruFocus.com
KNSA (Kiniksa Pharmaceuticals International) EV-to-Revenue : 4.87 (As of Aug. 16, 2024) - GuruFocus.com
KNSA (Kiniksa Pharmaceuticals International) PE Ratio (TTM) : At Loss (As of Aug. 18, 2024) - GuruFocus.com
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):